Diabetic Retinopathy Epidemiology Forecast 2025-2034

Diabetic retinopathy is a diabetes complication which affects the eyes. It is brought on by harm to the blood vessels in the back of the eye's light-sensitive tissue. Any person with type 1 or type 2 diabetes may develop the condition. Several studies suggest that the prevalence of diabetic retinopathy among diabetic patients is estimated to be 27.0% globally.

Diabetic Retinopathy Epidemiology Forecast Report Coverage

The “Diabetic Retinopathy Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of diabetic retinopathy. It projects the future incidence and prevalence rates of diabetic retinopathy across various populations. The study covers age and type as major determinants of the diabetic retinopathy-affected population. The report highlights patterns in the prevalence of diabetic retinopathy over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of diabetic retinopathy in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Diabetic Retinopathy: Disease Overview

Diabetic retinopathy is a progressive eye disease which occurs due to prolonged high blood sugar levels in diabetic patients leading to damage in the blood vessels of the retina. It goes through several stages, from proliferative diabetic retinopathy, where new abnormal blood vessels grow and cause bleeding and vision loss, to mild non-proliferative retinopathy, characterized by slight swelling in retinal vessels. Blurred vision, floaters, trouble seeing color, and in extreme situations, blindness, are some of the symptoms. The disease is more likely to occur when risk factors like high cholesterol, hypertension, and poor blood sugar control are present.

Diabetic Retinopathy: Treatment Overview

The treatment for the disease depends on the severity and stage of diabetic retinopathy determine. Anti-VEGF injections (such as ranibizumab or aflibercept) or corticosteroid injections may be used to treat macular edema, or swelling in the central retina, in order to improve vision. Leaking blood vessels can also be sealed with laser treatment, also known as focal laser therapy. Treatment intensifies when proliferative diabetic retinopathy (PDR) reaches advanced stages. Pan-retinal photocoagulation (PRP), a type of laser therapy, is used to shrink abnormal blood vessels and prevent further growth. In cases of severe bleeding or retinal detachment, a surgical procedure called vitrectomy is performed to remove blood or scar tissue from the vitreous gel and repair the retina.

Epidemiology

The diabetic retinopathy epidemiology section offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for diabetic retinopathy by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for diabetic retinopathy and their trends. The data is broken down into specific categories, such as the total diagnosed cases across different age groups and patient pools.

• The International Diabetic Federation estimated that the global prevalence of diabetic retinopathy was more than 25% in 2019. The number of people who are blind due to diabetic retinopathy grew from 0.2 million to 0.4 million globally. Moreover, approximately 80% of people with type 2 diabetes are expected to develop retinopathy.
• According to the Centers for Disease Control, an estimated 9.6 million people in the United States were living with diabetic retinopathy in 2021.
• According to the study conducted by NCBI in 21 districts of India, it was revealed that the prevalence of diabetic retinopathy among persons with diabetes was 16.9%, the prevalence of STDR was 3.6%, and the prevalence of mild retinopathy was 11.8%.
• According to the American Academy of Ophthalmology, 3%-4.1% of Europeans are affected by diabetic retinopathy.

Country-wise Diabetic Retinopathy Epidemiology

Diabetic retinopathy epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of diabetic retinopathy varies across countries based on diabetes prevalence, healthcare access, and neurological disease burden. According to the Centers for Disease Control, in 2021, in the United States, there were 8.94 million people aged =40 years with diabetic retinopathy and 1.71 million people aged =40 years with vision-threatening diabetic retinopathy.

Scope of the Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification of diabetic retinopathy based on several factors.
• The Diabetic Retinopathy Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The report helps to identify the patient population, and the unmet needs of diabetic retinopathy are highlighted along with an assessment of the disease's risk and burden.

Key Questions Answered

• What are the key findings of diabetic retinopathy epidemiology in the 8 major markets?
• What will be the total number of patients with diabetic retinopathy across the 8 major markets during the forecast period?
• What was the country-wise prevalence of diabetic retinopathy in the 8 major markets in the historical period?
• Which country will have the highest number of diabetic retinopathy patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of diabetic retinopathy during the forecast period of 2025-2034?
• What are the currently available treatments for diabetic retinopathy?
• What are the disease risks, signs, symptoms, and unmet needs of diabetic retinopathy?

This product will be delivered within 3-5 business days.